Coherus Oncology (CHRS) Total Current Liabilities (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Total Current Liabilities data on file, last reported at $132.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 48.11% year-over-year to $132.3 million; the trailing twelve-month figure through Mar 2026 stood at $132.3 million (down 48.11% YoY), and the FY2025 full-year result was $140.4 million, down 50.39% from the prior year.
• Total Current Liabilities eased to $132.3 million in Q1 2026, from $140.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $538.3 million in Q1 2024 to a low of $123.4 million in Q1 2023.
• A 5-year average of $247.8 million and a median of $239.7 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 336.2% in 2024 and sank 52.62% in 2025, its largest moves.
• Tracing CHRS's Total Current Liabilities over 5 years: stood at $138.7 million in 2022, then soared by 139.21% to $331.8 million in 2023, then slipped by 14.71% to $283.0 million in 2024, then sank by 50.39% to $140.4 million in 2025, then slipped by 5.74% to $132.3 million in 2026.
• Business Quant data shows CHRS's Total Current Liabilities at $132.3 million in Q1 2026, $140.4 million in Q4 2025, and $372.3 million in Q3 2025.